SBRT for Oligoprogressive Renal Cell Carcinoma and Prostate Cancer: A Case-Based Panel Discussion

Use of SABR for selected patients with oligoprogressive (OP) prostate cancer and renal cell carcinoma (RCC) has been shown to have the potential to improve progression-free survival, extend the time to developing new metastatic lesions, and delay time to starting next systemic therapy without adding significant toxicity – although most of these studies have been small Phase II, single institution, or “basket” trials with heterogeneity in histologies and systemic therapies utilized. OP disease is distinct from oligometastatic disease at presentation, with lack of agreement in its definition. Since not all patients appear to benefit from SABR for OP disease, there is a strong need to recognize patient/disease characteristics and use existing biomarkers, such as ctDNA, to best identify patients who will most benefit from local therapy and experience prolonged time to further distant progression requiring change in systemic treatment. While randomized phase III trials evaluating the use of local therapies in the setting of OP prostate and RCC are ongoing, this approach has already been incorporated into the current standard management of these patients. In this activity, we present the current evidence regarding the use of SABR for OP prostate and RCC and recommendations for best current clinical practice in the use of SABR for patients with OP prostate cancer and RCC will be provided using case-based examples.  

This activity is available from July 9, 2026, through 11:59 p.m. Eastern time on July 8, 2028. 

 

Target Audience

The activity is designed to meet the interests of radiation oncologists, urologists and residents.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze the current evidence for the use of SABR in the multidisciplinary management of oligoprogressive prostate cancer and renal cell carcinoma. 
  • Discuss recent clinical trials studying the use of SABR for patients with oligoprogressive prostate cancer and renal cell carcinoma. 
  • Implement an algorithm for best utilization of SABR for oligoprogressive prostate cancer/renal cell carcinoma in the context of current systemic therapies, recognizing specific patient and disease characteristics.

 

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
07/09/2026
Course expires: 
07/08/2028
Cost:
$149.00
Rating: 
0

Speakers:

  • Krishna Reddy, MD, PhD, is employed by University of Kansas Medical Center. Dr. Reddy has no relevant financial relationship with ineligible companies to disclose.  
  • Xinglei Shen, MD, is employed by University of Kansas Medical Center. Dr. Shen receives research/grant funding from Sumitomo Pharmaceuticals, Pfizer Pharmaceuticals and Artera AI. 
  • Muhammad Ali, MBBS, FCPS, FRANZCR, is employed by Peter MacCallum Cancer Centre. Dr. Ali has no relevant financial relationship with ineligible companies to disclose.  

Planners:

  • Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 
     

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$149.00
Please login or register to take this course.

Activity Fees

This activity is included in the ASTRO Academy Subscription. To purchase the subscription beginning December 1, 2026, please go to the ASTRO Product Catalog.

ASTRO members and Academy subscribers must log in to the ASTRO Academy to view and receive the corresponding rate:

  • Academy Subscriber: $0
  • Member: $99
  • Member-in-Training / Student Member / Postdoctoral Fellow Member: $49
  • Nonmember: $149

Discounts
Please email ASTRO eLearning to inquire about the discounts below.

  • If you are an ASTRO member residing in a low- or lower-middle-income economy country, as identified by the World Bank, you can receive a 50% discount off the activity fee.
  • If you are an ASTRO member residing in an upper-middle-income economy country, as identified by the World Bank, you can receive a 25% discount off the activity fee.

Policies

No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until the Activity expiration date, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.

Copyright of all aspects of ASTRO Academy Content, including recordings and/or reproductions of sessions, programs, presentations, discussions and other scheduled events (“ASTRO Academy Content”) is owned by ASTRO. Only ASTRO reserves the rights to all ASTRO Academy Content, including to digitize, modify, alter, edit, adapt, create derivative works, display, publicly perform, exhibit, transmit, broadcast, reproduce, exploit, sell, rent license, otherwise use, and permit others to use, such ASTRO Academy Content. Photographing, filming, taping, recording or any form of capture or reproduction in any medium of any aspect of ASTRO Academy Content, including, but not limited to the programs, presentations, material, sessions, and discussions, or on the Academy platform are strictly forbidden without written authorization from ASTRO.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.